Search

Your search keyword '"Icardi G"' showing total 550 results
Start Over Author "Icardi G"
550 results on '"Icardi G"'

112. Sequential outbreaks of multidrug-resistant Acinetobacter baumannii in intensive care units of a tertiary referral hospital in Italy: combined molecular approach for epidemiological investigation

Author

Ansaldi, F., primary, Canepa, P., additional, Bassetti, M., additional, Zancolli, M., additional, Molinari, M.P., additional, Talamini, A., additional, Ginocchio, F., additional, Durando, P., additional, Mussap, M., additional, Orengo, G., additional, Viscoli, C., additional, and Icardi, G., additional

Published
2011
Full Text
View/download PDF

114. Ras-Induced Resistance to Lapatinib is Overcome by MEK Inhibition

Author

Zoppoli, G., primary, Moran, E., additional, Soncini, D., additional, Cea, M., additional, Garuti, A., additional, Rocco, I., additional, Cirmena, G., additional, Grillo, V., additional, Bagnasco, L., additional, Icardi, G., additional, Ansaldi, F., additional, Parodi, S., additional, Patrone, F., additional, Ballestrero, A., additional, and Nencioni, A., additional

Published
2010
Full Text
View/download PDF

119. A comparison of hepatitis B seroepidemiology in ten European countries

Author

NARDONE, A., primary, ANASTASSOPOULOU, C. G., additional, THEETEN, H., additional, KRIZ, B., additional, DAVIDKIN, I., additional, THIERFELDER, W., additional, O'FLANAGAN, D., additional, BRUZZONE, B., additional, MOSSONG, J., additional, BOOT, H. J., additional, BUTUR, D., additional, SLAČIKOVÁ, M., additional, PANAIT, M. L. C., additional, HELLENBRAND, W., additional, DE MELKER, H., additional, SOBOTOVÁ, Z., additional, ICARDI, G., additional, ANDREWS, N., additional, PEBODY, R. G., additional, VAN DAMME, P., additional, KAFATOS, G., additional, MILLER, E., additional, and HATZAKIS, A., additional

Published
2008
Full Text
View/download PDF

122. Safety and Immunogenicity of Two Influenza Virus Subunit Vaccines, with or without MF59 Adjuvant, Administered to Human Immunodeficiency Virus Type 1-Seropositive and -Seronegative Adults

Author

Durando, P., primary, Fenoglio, D., additional, Boschini, A., additional, Ansaldi, F., additional, Icardi, G., additional, Sticchi, L., additional, Renzoni, A., additional, Fabbri, P., additional, Ferrera, A., additional, Parodi, A., additional, Bruzzone, B., additional, Gabutti, G., additional, Podda, A., additional, Del Giudice, G., additional, Fragapane, E., additional, Indiveri, F., additional, Crovari, P., additional, and Gasparini, R., additional

Published
2008
Full Text
View/download PDF

135. Antiviral activity of amantadine in elderly patients with chronic hepatitis C.

Author

Torre, F., Campo, N., Giusto, R., Ansaldi, F., Icardi, G. C., and Picciotto, A.

Subjects
AMANTADINE, HEPATITIS C, HEPATITIS C virus, OLDER people, RNA, RNA analysis, ANTIVIRAL agents, CLINICAL trials, COMPARATIVE studies, DRUG administration, DOSE-effect relationship in pharmacology, HEPATITIS viruses, LONGITUDINAL method, RESEARCH methodology, MEDICAL cooperation, NONPARAMETRIC statistics, ORAL drug administration, RESEARCH, EVALUATION research, TREATMENT effectiveness, CHRONIC hepatitis C, DIAGNOSIS
Abstract

Background: Hepatitis C virus (HCV) infection is a worldwide problem of public health. Epidemiological studies have shown a significant higher prevalence of infection in the elderly. Amantadine is an antiviral agent active against the influenza A virus that has been used in cases of chronic hepatitis C.Objectives: To evaluate the antiviral activity and the safety of amantadine (200 mg daily for 6 months) in elderly patients with chronic hepatitis C.Methods: The study group consisted of 23 consecutive patients over 65 years suffering from chronic hepatitis C. Aminotransferase (ALT) levels were tested at baseline, at 15 days and then monthly until the end of therapy. HCV genotype was determined at baseline. A quantitative HCV-RNA measurement was performed at baseline, at 15 days and at the 1st, 3rd and 6th month of treatment.Results: 13 males and 10 females were enrolled (mean age 70.1 +/- 3.4 years; range: 65-75). The mean ALT levels did not change significantly during therapy except in 1 patient subsequently returned normal. The HCV-RNA remained detectable in all patients, but a significant difference in response was observed in patients infected by genotype 1b.Conclusions: Our results confirm the antiviral activity of amantadine against HCV, mainly for genotype 1b with initial high viral load. No consistent effects on aminotransferases were observed. [ABSTRACT FROM AUTHOR]

Published
2001
Full Text
View/download PDF

137. The 2014 lifetime immunization schedule approved by the Italian scientific societies. Italian Society of Hygiene, Preventive Medicine, and Public Health. Italian Society of Pediatrics. Italian Federation of Pediatric Physicians. Italian Federation of General Medical Physicians. Arezzo Service of Legal Medicine,Il calendario vaccinale per la vita 2014 predisposto dalle società scientifiche italiane

Author

Bonanni, P., Chiara Azzari, Castiglia, P., Chiamenti, G., Conforti, G., Conversano, M., Corsello, G., Ferrera, G., Ferro, A., Icardi, G., Macrì, P. G., Maio, T., Ricciardi, W., Russo, R., Scotti, S., Signorelli, C., Sudano, L., Ugazio, A. G., Villani, A., Vitali Rosati, G., Bonanni, P., Azzari, C., Castiglia, P., Chiamenti, G., Conforti, G., Conversano, M., Corsello, G., Ferrera, G., Ferro, A., Icardi, G., Macrì, P. G., Maio, T., Ricciardi, W., Russo, R., Scotti, S., Signorelli, C., Sudano, L., Ugazio, A. G., Villani, A., Vitali Rosati, G., Macrì, P., and Ugazio, A.

Subjects
Adult, Secondary, Adolescent, Age Factors, Aged, Child, Child, Preschool, Humans, Immunization, Secondary, Infant, Infant, Newborn, Italy, Middle Aged, Societies, Medical, Vaccination, Vaccines, Young Adult, Immunization Schedule, Medical, Age Factor, Preschool, Newborn, Settore MED/38, Immunization, Societies, Vaccine, Human

142. Host defenses during prolonged alcohol consumption in a controlled environment

Author

Boccalini, S., Bonanni, P., Azzari, C., Camilloni, B., Castiglia, P., Chiamenti, G., Conversano, M., Esposito, S., Francia, F., Franco, E., Icardi, G., Villani, A., Vitali Rosati, G., and Vitale, F.

Subjects
Adult, Male, chemical and pharmacologic phenomena, Alcohol, Cell Count, Granulocyte, Antibodies, chemistry.chemical_compound, Immune system, Internal Medicine, Medicine, Humans, Granulocyte chemotaxis, Aged, età pediatrica, Immunity, Cellular, biology, business.industry, Immunity, Middle Aged, Alcoholism, Chemotaxis, Leukocyte, Clinical research, medicine.anatomical_structure, chemistry, Immunization, Delayed hypersensitivity, Immunology, Hemocyanins, biology.protein, vaccinazione antinfluenzale, business, Keyhole limpet hemocyanin, vaccinazione antinfluenzale, età pediatrica, Granulocytes
Abstract

To determine the pure effects of prolonged alcohol ingestion on host defenses, we studied six noncirrhotic alcoholic volunteers drinking in the Clinical Research Center. All had tests of granulocyte, humoral, and cell-mediated immune function before and at the end of eight to 28 days' intake of approximately 0.75 liter of 100-proof whiskey per day. Results of all tests were normal during the drinking period, except for the following: (1) granulocyte chemotaxis was depressed in three volunteers and improved on alcohol withdrawal; (2) antibody response to keyhole limpet hemocyanin (KLH) immunization was poor; and (3) delayed hypersensitivity could not be established to KLH. Although it is somewhat surprising that more abnormalities were not induced, the three defects noted may contribute to the alcoholic's poor resistance to infection. ( Arch Intern Med 137:1539-1543, 1977)

Published
1977

148. Anti-hepatitis C virus antibodies and hepatitis C virus viraemia in haemodialysis patients.

Author

Piciotto, A., Varagona, G., Gurreri, G., Fiorini, F., Sofia, A., Coviello, D. A., Bonanni, P., Icardi, G. C., Valle, F., and Celle, G.

Abstract

Sera from 82 haemodialysis patients were tested for anti-HCV, HCV-RNA, and HBsAg. Alanine aminotransferase (ALT) activity was monitored weekly for 2 months. Anti-HCV was positive in 31 patients (37.8%), showing different single-peptide patterns. HCV-RNA was detected in 26 anti-HCV-positive patients (84%) and also in two of 21 anti-HCV-negative patients. Twenty-seven (87%) of the 31 anti-HCV-positive patients had persistently normal ALT values; 22 of these patients were HCV-RNA positive. The four patients with elevated ALT values had HCV viraemia. HBsAg was positive in nine anti-HCV-negative patients. The close correlation between HCV viraemia and HCV status, independently of ALT values, requires that anti-HCV dialysis patients must be considered potentially infective and dialysed with reserved machines and/or in separate shifts. [ABSTRACT FROM PUBLISHER]

Published
1993

149. Consensus document and recommendations for the prevention of cardiovascular disease in Italy - 2018,Documento di consenso e raccomandazioni per la prevenzione cardiovascolare in Italia 2018

Author

Volpe, M., Tocci, G., Accettura, D., Battistoni, A., Costanzo, G., Rubattu, S., Volpe, R., Bellone, S., Ricotti, R., Bellotti, P., Bertolotti, M., Modena, M. G., Borghi, C., Casasco, M., Rizzoni, D., Consoli, A., Coppini, R., Galanti, G., Niccolò Lombardi, Modesti, P. A., Mugelli, A., Rotella, C., Corsini, A., Parati, G., Perseghin, G., Desideri, G., Ferri, C., Giada, F., Icardi, G., Orsi, A., Monti, G., Pedretti, R. F. E., Pirro, M., Salvetti, G., Sarto, P., Tassinari, F., Trimarco, B., and Kreutzenberg, S. V.

Catalog

Books, media, physical & digital resources
See catalog results